Spironolactone Tablet, Film Coated
Product Images NDC 59746-218

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 59746-218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmacuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg Bottle Label (100mg)

Spironolactone Tablets USP 100 mg film-coated oral tablets label, with 100 tablets per container. Label shows dosage strength, manufacturer Jubilant Generics Ltd., and marketer Jubilant Cadista Pharmaceuticals Inc. Includes storage instructions, barcode, and imprint "TL 218" on tablets. Marked Rx only.*

FDA Label Image

25mg Bottle Label (25mg)

Packaging label for Spironolactone Tablets, USP 25 mg film-coated tablets. The label states a count of 100 tablets, includes manufacturer Jubilant Generics Ltd. and marketer Jubilant Cadista Pharmaceuticals Inc. It features dosage information, storage instructions, and two images of the round, peach-colored tablets. The label bears barcodes and the Cadista logo.*

FDA Label Image

50mg Bottle Label (50mg)

Label for Spironolactone Tablets USP 50 mg film-coated tablets, packaged in a bottle containing 100 tablets. The label includes dosage information, storage instructions, and manufacturer details by Jubilant Generics Ltd. and marketed by Jubilant Cadista Pharmaceuticals Inc. The label features two orange, round tablets and a barcode.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of spironolactone showing its steroidal core with functional groups including ketone and thioacetate moieties.*

FDA Label Image

Figure01 (Fig01)

A Kaplan-Meier survival plot comparing the probability of an event over 48 months for two groups: Spironolactone (n=822) and Placebo (n=841). The x-axis shows time in months, and the y-axis shows the probability. The plot includes a statistical significance value (Log-rank p < 0.001), indicating a notable difference between groups.*

FDA Label Image

Figure02 (Fig02)

A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) across various patient subgroups for a study comparing spironolactone versus placebo. The subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA classification, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The chart visually indicates whether spironolactone or placebo is favored for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.